Headache as a Prognostic Factor for COVID-19. Time to Re-evaluate
- PMID: 33263101
- PMCID: PMC7690334
- DOI: 10.1007/s42399-020-00657-7
Headache as a Prognostic Factor for COVID-19. Time to Re-evaluate
Abstract
Headache occurs in only about 13% of patients within the cohort of presenting COVID-19 symptoms. The hypothesis that such a painful symptomatic picture could be considered a prognostic factor for COVID-19 positive evolution or its trend of severity, or the co-generation of hyposmia/anosmia and/or hypogeusia/ageusia, needs robust epidemiological data, punctual pathophysiological demonstrations, and a detailed comparative analysis on drug-drug interactions (DDIs).
Keywords: COVID-19; Cytokine release syndrome (CRS); Drug–drug interactions (DDIs); Emergency medicine; Headache; Prognostic factors.
© The Author(s) 2020.
Conflict of interest statement
Conflict of InterestThe authors declare that they have no conflict of interest.
References
-
- https://pubmed.ncbi.nlm.nih.gov/?term=COVID-19&sort=date (last accessed 9 November 2020).
-
- https://covid19.who.int (last accessed 9 November 2020).
-
- Caronna E, Ballvé A, Llauradó A, Gallardo VJ, Ariton DM, Lallana S, López Maza S, Olivé Gadea M, Quibus L, Restrepo JL, Rodrigo-Gisbert M, Vilaseca A, Hernandez Gonzalez M, Martinez Gallo M, Alpuente A, Torres-Ferrus M, Pujol Borrell R, Alvarez-Sabin J, Pozo-Rosich P. Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020;40(13):1410–1421. doi: 10.1177/0333102420965157. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources